The Moderna ‘Channel’ … Redux

… And The Weekly, ‘Summary & Strategy’

The last update about our chief cook and bottle washer of gene ‘modification’ had this to say about price action.

“We’re about forty minutes into the session; Moderna (MRNA) has just confirmed the up-thrust reversal discussed in the last update“.

From that point Moderna (MRNA) declined for seven weeks for a total of around – 31.5%.

However, that’s not the most important part.

In that update, a trading channel was shown which at the time, was declining at – 93.7%, on an annualized basis.

Well, the channel is back.

Only this time, probabilities and price action have come together to set up for a potential sustained decline.

Moderna MRNA, Weekly

Above, we have a Wyckoff ‘Up-Thrust’ and a test that has since turned lower.

Next, we have a series of repeating trend or channel lines.

Additional data has modified the downward slope to be declining at approximately – 90%, annualized.

From a fundamental standpoint, the data set is enormous on the events of the past three years.

At some point that data could provide a huge tailwind for downside action.

For now however, let’s stick with what price action is telling us and go to the Summary & Strategy

Summary & Strategy

The past week has identified two areas of position or trade execution and two areas for possible short-term options execution (not advice, not a recommendation):

Position or Trade: Real Estate IYR, and Biotech SPBIO

Options: Carmax KMX, and Moderna MRNA

As a reminder, most if not all trade analysis is for the short side (not advice, not a recommendation).

Final Thoughts

Since we have possibly the largest bull trap in market history with huge numbers of VIX Call options, the following week may be subdued by going modestly up, sideways or down, slowly.

With that said, options positioning (if any) could be slated for the week of 2/17/23.

As always, price action is the final arbiter.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

The Danger Point®, trade mark: No. 6,505,279

%d bloggers like this: